Effect of cilostazol in the treatment of acute ischemic stroke in the lenticulostriate artery territory

European Neurology

Volumn 69, Issue 2, 2013, Pages 122-128

  Kondo, Ryushi ^a   Matsumoto, Yasushi ^a   Furui, Eisuke ^a   Itabashi, Ryo ^a   Sato, Shoichiro ^a   Yazawa, Yukako ^a   Shimizu, Hiroaki ^a   Fujiwara, Satoru ^a   Takahashi, Akira ^a   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Acute ischemic stroke; Cilostazol; Lacunar infarcts; Lenticulostriate artery; Perforating artery

Indexed keywords

CILOSTAZOL; OZAGREL;

AGED; ARTICLE; BRAIN ARTERY; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; LENTICULOSTRIATE ARTERY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; TREATMENT OUTCOME;

EID: 84870295059     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000343799     Document Type: Article

References (32)

1. Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M, Sugihara H, Morita Y, Hirose K, Okayama A, Miura K, Ueshima H. Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988-2004. Stroke 2010; 41: 1871-1876.
2. Kim YB, Moon HS, Suh BC, Park KY, Lee YT, Chung PW. Topographic patterns and stroke subtypes according to progressive motor deficits in lacunar syndrome. J Stroke Cerebrovasc Dis 2011; 20: 352-356.
3. Ohara T, Yamamoto Y, Tamura A, Ishii R, Murai T. The infarct location predicts progressive motor deficits in patients with acute lacunar infarction in the lenticulostriate artery territory. J Neurol Sci 2010; 293: 87-91.
4. Rödén-Jüllig A, Britton M, Malmkvist K, Leijd B. Aspirin in the prevention of progressing stroke: a randomized controlled trial. J Intern Med 2003; 254: 584-590.
5. Rödén-Jüllig A, Britton M. Effectiveness of heparin treatment for progressing ischemic stroke: before and after study. J Intern Med 2000; 248: 287-291.
6. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003; 9: 2289-2302.
7. Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type 3 phosphodiesterase, produce endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles. J Vasc Res 2006; 43: 86-94.
8. Matsumoto T, Noguchi E, Ishida K, Nakayama N, Kobayashi T, Kamata K. Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from type 2 diabetic rats. Eur J Pharmacol 2008; 599: 102-109.
9. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC, Kim JS. Cilostazol in acute ischemic stroke treatment (CAIST Trial): a randomized double-blind non-inferior trial. Cerebrovasc Dis 2011; 32: 65-71.
10. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Masuda T, Sawada T, Yamaguchi T, Nishimura K, Ohashi Y. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157.
11. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Harada S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C for the CSPS 2 group: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferior trial. Lancet Neurol 2010; 9: 959-968.
12. Lasjaunias P, Berenstein A, ter Brugge KG. The middle cerebral artery; in Lasjaunias P, Berenstein A, ter Brugge KG (eds): Surgical Neuroangiography, ed 2. Berlin, Springer, 2001, vol 1, pp 613-614
13. Pullicino P. Lenticulostriate arteries; in Bogousslavsky J, Caplan L (eds): Stroke Syndromes, ed 2. Cambridge, Cambridge University Press, 2001, pp 428-438.
14. Oishi M, Mochizuki Y, Hara M, Yoshihashi H, Takasu T. Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction. Clin Neuropharmacol 1996; 19: 526-531.
15. Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982; 32: 871-876.
16. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol 1968; 12: 1-15.
17. Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology 1989; 39: 1246-1250.
18. Yamamoto Y, Ohara T, Hamanaka M, Hosomi A, Tamura A, Akiguchi T. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci 2011; 304: 78-82.
19. Lee KB, Oh HG, Roh H, Ahn MY. Can we discriminate stroke mechanisms by analyzing the infarct patterns in the striatocapsular region?. Eur Neurol 2008; 60: 79-84.
20. Fisher CM. Capsular infarcts: the underlying vascular lesions. Arch Neurol 1979; 36: 65-73.
21. Fisher CM, Caplan LR. Basilar artery branch occlusion: a case of pontine infarction. Neurology 1971; 21: 900-905.
22. Wardlaw JM, Sandercock PAG, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?. Stroke 2003; 34: 806-812.
23. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006; 37: 1391-1398.
24. Wardlaw JM, Doubal F, Armitage P, Chappell F, Carpenter T, Muñoz Maniega S, Farrall A, Sudlow C, Dennis M, Dhillon B. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann Neurol 2009; 65: 194-202.
25. Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal appearing white matter in patients with lacunar stroke and leukoaraiosis. J Neurol Neurosurg Psychiatry 2010; 81: 192-197.
26. Ma KC, Olsson Y. Structural and vascular permeability abnormalities with lacunes of human brain. Ann Neurol Scand 1993; 88: 100-107.
27. Wardlaw JM, Dennis MS, Warlow CP, Sandercock PA. Imaging appearance of the symptomatic perforating artery in patients with lacunar infarction: occlusion or other vascular pathology?. Ann Neurol 2001; 50: 208-215.
28. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-398.
29. Torii H, Kubota H, Ishihara H, Suzuki M. Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation. Pharmacol Res 2007; 55: 104-110.
30. Yamamoto Y, Ohara T, Ishii R, Tanaka E, Murai T, Morii F, Tamura A, Ohara R. A combined treatment for acute larger lacunar-type infarction. J Stroke Cerebrovasc Dis 2011; 20: 387-394.
31. Otomo E, Kutsuzawa T, Kogure K, Hirai S, Goto F, Terashi A Takazaki A, Tazaki Y, Araki G, Ito E, Fujishima M, Nakashima M. Clinical usefulness of OKY-046 on the acute stage of cerebral thrombosis: double-blind trial in comparison with placebo (in Japanese with English abstract). J Clin Therapeut Med 1991; 7: 353-388.
32. Shinohara Y, Yamaguchi T. Outline of the Japanese guidelines for the management of stroke 2004 and subsequent revision. Int J Stroke 2008; 3: 55-62.